These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 10178664)

  • 1. An introduction to Markov modelling for economic evaluation.
    Briggs A; Sculpher M
    Pharmacoeconomics; 1998 Apr; 13(4):397-409. PubMed ID: 10178664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of pharmacoeconomics in prescribing research. Part 5: modelling--beyond clinical trials.
    Lang DL; Lopert R; Hill SR
    J Clin Pharm Ther; 2003 Oct; 28(5):433-9. PubMed ID: 14632969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of pharmacoeconomic modelling methods.
    Ademi Z; Kim H; Zomer E; Reid CM; Hollingsworth B; Liew D
    Br J Clin Pharmacol; 2013 Apr; 75(4):944-50. PubMed ID: 22882459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incorporation of potential confounding variables in Markov models.
    Nuijten MJ; Rutten F
    Pharmacoeconomics; 2003; 21(13):941-50. PubMed ID: 12959626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts.
    Bala MV; Mauskopf JA
    Pharmacoeconomics; 2006; 24(4):345-54. PubMed ID: 16605281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous-Time Semi-Markov Models in Health Economic Decision Making: An Illustrative Example in Heart Failure Disease Management.
    Cao Q; Buskens E; Feenstra T; Jaarsma T; Hillege H; Postmus D
    Med Decis Making; 2016 Jan; 36(1):59-71. PubMed ID: 26174352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporation of uncertainty in health economic modelling studies.
    O'Hagan A; McCabe C; Akehurst R; Brennan A; Briggs A; Claxton K; Fenwick E; Fryback D; Sculpher M; Spiegelhalter D; Willan A
    Pharmacoeconomics; 2005; 23(6):529-36. PubMed ID: 15960550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations.
    Nuijten MJ
    Pharmacoeconomics; 2004; 22(12):759-69. PubMed ID: 15294010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling in the economic evaluation of health care: selecting the appropriate approach.
    Barton P; Bryan S; Robinson S
    J Health Serv Res Policy; 2004 Apr; 9(2):110-8. PubMed ID: 15099459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom.
    Claxton L; Hodgson R; Taylor M; Malcolm B; Pulikottil Jacob R
    Pharmacoeconomics; 2017 Feb; 35(2):237-248. PubMed ID: 27787744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interest of modelling in rheumatoid arthritis.
    Beresniak A; Dupont DM; Becker JC; Merkesdal S
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S96-101. PubMed ID: 23078913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decision-analytical modelling in health-care economic evaluations.
    Sun X; Faunce T
    Eur J Health Econ; 2008 Nov; 9(4):313-23. PubMed ID: 17943332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Principles of pharmacoeconomic analysis of drug therapy.
    Freund DA; Dittus RS
    Pharmacoeconomics; 1992 Jan; 1(1):20-31. PubMed ID: 10147037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selecting a decision model for economic evaluation: a case study and review.
    Karnon J; Brown J
    Health Care Manag Sci; 1998 Oct; 1(2):133-40. PubMed ID: 10916592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation and review of pharmacoeconomic models.
    Hay JW
    Expert Opin Pharmacother; 2004 Sep; 5(9):1867-80. PubMed ID: 15330725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applied pharmacoeconomics: modeling data from internal and external sources.
    Sanchez LA; Lee JT
    Am J Health Syst Pharm; 2000 Jan; 57(2):146-55; quiz 155-6. PubMed ID: 10688243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression.
    Zaric GS
    Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An introduction to the methods of decision-analytic modelling used in economic evaluations for Dermatologists.
    McManus E; Sach TH; Levell NJ
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1829-1836. PubMed ID: 31127965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process.
    Li F; Jörg F; Li X; Feenstra T
    Pharmacoeconomics; 2022 Nov; 40(11):1015-1032. PubMed ID: 36100825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mathematical approach for evaluating Markov models in continuous time without discrete-event simulation.
    van Rosmalen J; Toy M; O'Mahony JF
    Med Decis Making; 2013 Aug; 33(6):767-79. PubMed ID: 23715464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.